As an alternative to morphine, researchers present a new nano-painkiller they've tested in rodents. In their study, three versions of their natural nanoparticle showed anti-pain effects when administered to inflamed rat paws. The new approach could open the door to treatments for intense pain without the severe side effects associated with morphine or related synthetic opioids, the authors say.
Chronic pain is highly prevalent around the world, an important global heath challenge. The most commonly used medications to treat it are morphine and synthetic opioids, which have severe side-effects - most notably, addiction. With more than 115 people dying after overdosing on opioids every day in the U.S., finding a new, less addictive painkiller is vital.
Small, naturally occurring peptides in the body like enkephalin, which bind to the body's opioid receptors, are an appealing option to treat pain because they activate δ-opioid receptor ligands, which are thought to have a lower abuse potential than receptors morphine activates. However, enkephalin-based approaches have not been adopted in the clinic because of pharmacokinetic problems, including difficulties for these peptides crossing the blood-brain-barrier.
In search of a better solution to control pain, researchers created a new nano-drug using Leu-enkephalin (LENK) neuropeptides. By connecting LENK to squalene, a natural and biocompatible lipid, the authors created nanoparticles that could be precisely delivered to the area of pain through intravenous injection.
In the swollen paws of rats four hours after the drug was administered, they saw signs of reduced thermal sensitivity to pain in all treated rats. Additionally, LENK-SQ NPs' pain-alleviating effect lasted longer than that achieved with morphine, the authors say. Real-time in vivo imaging of the rats after intravenous injection of fluorescent DiD-labeled LENK-SQ-Am NPs showed that a significant portion of the NPs reached the inflamed tissue, with no indication of toxicity. Further analysis revealed the LENK-SQ nanoparticles acted through peripherally located opioid receptors, which have a lower abuse potential than those morphine activates.
http://advances.sciencemag.org/content/5/2/eaau5148
Less addictive nano-painkiller that lasts longer!
- 1,046 views
- Added
Edited
Latest News
Abusive drugs hijack natura…
By newseditor
Posted 23 Apr
Mechanism of action of the…
By newseditor
Posted 23 Apr
Role of fat in rare neurolo…
By newseditor
Posted 23 Apr
How protein synthesis in de…
By newseditor
Posted 22 Apr
Atlas of mRNA variants in d…
By newseditor
Posted 22 Apr
Other Top Stories
Fourth wheat gene key to flowering and climate adaptation identified
Read more
Mechanism of TNT toxicity in plants
Read more
A new cyanogenic metabolite in Arabidopsis required for inducible p…
Read more
How cancer drug Taxol protects the plants against the pathogen
Read more
Detoxification of host plant's chemical by the larvae
Read more
Protocols
A programmable targeted pro…
By newseditor
Posted 23 Apr
MemPrep, a new technology f…
By newseditor
Posted 08 Apr
A tangible method to assess…
By newseditor
Posted 08 Apr
Stem cell-derived vessels-o…
By newseditor
Posted 06 Apr
Single-cell biclustering fo…
By newseditor
Posted 01 Apr
Publications
Exploiting pancreatic cance…
By newseditor
Posted 23 Apr
Structure of antiviral drug…
By newseditor
Posted 23 Apr
Type-I-interferon-responsiv…
By newseditor
Posted 23 Apr
Selenium, diabetes, and the…
By newseditor
Posted 23 Apr
Long-term neuropsychologica…
By newseditor
Posted 23 Apr
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar